There has been continued interest in the development of oral /Mactam antibiotics that can be used to treat infections caused by Gram-positive and Gram-negative bacteria1^. KT3777 (LY163892, Eli Lilly) is a novel oral /Mactam antibiotic in the carbacephem class. That was synthesized by KyowaHakko Kogyo Co., Ltd.4~6). Its chemical name is 7-[D-(aminophenylacetyl)amino]-3-chloro-8-oxo-l-azabicyclo-[4,2,0]oct-2-ene-2-carboxylic acid. Chemical structure is shown in Fig. 1 . Its structure is similar to that of cefaclor (CCL), the only difference being substitution of carbon for sulfur at the number 1 position in the dihydrothiazine ring. KT3777possesses an antibacterial spectrum virtually identical to that of CCL7 '8) . KT3777 resists hydrolysis by plasmid-mediated /Mactamase9). Previous experience in our laboratory indicated that KT3777has greater bioavailability superior to that of CCLafter oral administration in experimental animal such as dogs and monkeys, and is more chemically stable than CCL10).
In this paper, we compared the in vitro and in vivo antibacterial activity of KT3777with those of CCL, cephalexin (CEX) and amoxicillin.
This work was presented in part at the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy1 0). 
Materials and Methods
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KT3777 was prepared at Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan. CCLand CEX(Shionogi & Co., Ltd., Osaka, Japan) and amoxicillin (Kyowa Hakko Kogyo Co., Ltd.) were obtained from commercial sources.
Organisms
Stock strains from the culture collection in our laboratories were used in this study. Clinical isolates of various species of bacteria were obtained from several hospitals in Japan. Anaerobes were kindly provided by Dr. K. Ueno, Institute of Anaerobic Bacteriology, Gifu University School of Medicine.
Determination of MIC
The MICof the test antibiotics were determined by the agar dilution method. Mueller-Hinton agar (Difco Laboratories, U.S.A.) was used for nonfastidious aerobic bacteria.
Mueller-Hinton agar supplemented with 5%defibrinated horse blood was used for Streptococcus species and Enterococcus species. Mueller-Hinton agar supplemented with 5%defibrinated horse blood and heated (chocolate agar) was used for Haemophilus influenzae. Thayer-Martin agar (Nissui, Japan) containing 1 % hemoglobin and GAMagar (Nissui) were used for Neisseria gonorrhoeae and anaerobic bacteria, respectively. All antibiotics solutions were freshly madeon the day of use. All strains except Streptococcus species, Enterococcus species, H. influenzae, N. gonorrhoeae and anaerobic bacteria were grown overnight in Mueller-Hinton broth (Difco) . Streptococcus species, Enterococcus species and H. influenzae were grown overnight in Mueller-Hinton broth plus 5% defibrinated horse blood. N. gonorrhoeae was grown overnight on
Thayer-Martin agar containing 1 %hemoglobin. GAMbroth was used for anaerobic bacteria. The overnight broth cultures and bacterial suspensions of N. gonorrhoeae were diluted to a final concentration of approximately 106 cfu/ml, and one loopful of each bacterial suspension, corresponding to about 104cfu, was inoculated (Microplanter; Sakuma Seisakusho, Japan) onto agar plates that contained 2-fold serial dilutions of antibiotics. The plates were incubated for 18 hours at 37°C except the methicillin-resistant Staphylococcus aureus and N. gonorrhoeae plates, which were incubated for 18 hours at 30°C and for 48 hours at 37°C, respectively. H. influenzae, N. gonorrhoeae and anaerobic bacteria were incubated in the GasPak system (BBL Microbiology Systems, U.S.A.) at 37°C. The MIC was defined as the lowest concentration of the antibiotic that prevented visible growth. The MIC50 and MIC90 were the concentrations of a drug required to inhibit 50%and 90%of strains, respectively.
Bactericidal Activity
The bactericidal activity of KT3777 was measured against Escherichia coli F3385 and Klebsiella pneumoniae F1928 in Mueller-Hinton broth. An overnight culture was suspended in fresh mediumat about 104cfu/ml and incubated at 37°C with shaking. After 2 hours of incubation, the test antibiotic was added to the culture at various concentrations around the MIC. At intervals during incubation for 6 hours at 37°C, samples were removed, immediately diluted in broth, and plated on Mueller-Hinton agar. The numbers of colonies were counted after 18 hours of incubation at 37°C.
Affinity for Penicillin-binding
Proteins (PBPs)
The affinity of KT3777for PBPs was examined by a competition method described previously11>12). A total membrane fraction was prepared from E. coli NIHJ JC-2 exponentially grown in Antibiotic medium No. 3 (Difco), and suspended at 20mg/ml in 0.05m sodium phosphate buffer. 100/xl of the membrane preparation was preincubated with 5/xl of either 0.05m phosphate buffer or a dilution of 54mCi/mmol, AmershamInternational pic, England) was added and incubated for a further 10 minutes at 30°C. The reaction was terminated by the addition of unlabeled benzylpenicillin and sarkosyl. After the suspension was allowed to stand for 20 minutes at 25°C, the inner membrane fraction (Sarkosyl soluble fraction) was obtained by centrifugation at 15,000 x g for 30 minutes at 25°C. The fraction was mixed with 50ju1 of 0.5m Tris-HCl buffer (pH6.8) containing sodium dodecyl sulfate 3% (w/v), glycerol 30% DEC. 1989 (w/v), bromphenol blue 0.002% (w/v), and lOjul of 2-mercaptoethanol, and heated in a boiling water bath for 3 minutes. 50jd of the solution was then subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis. After electrophoresis, the gel was fixed in 300ml of 50% methanol-7%acetic acid for 1 hour at room temperature and washed 5 times for 0.5 hour with 300ml of 5% methanol -7%acetic acid.
The gel was soaked in 300ml of 20% (w/v) 2,5-diphenyloxazole (PPO) in dimethyl sulfoxide with gentle shaking for 3 hours, washed in water, and dried in vacuo on WhatmanNo. 3 MMpaper. A fluorogram was prepared by exposing the gel to X-ray film (Ultrofilm 3H, LKB) at -80°C for 3 months. The concentration of antibiotics required for 50% binding inhibition of 14C-labeled benzylpenicillin to PBPs (IC5Os) were determined with a densitometer (Model CS-900, Shimadzu, Japan).
Experimental Infections in Mice
Systemic Infections: Ten 4-week-old male ddY strain mice weighing 18 to 20g were used for each dose level. Test organisms were cultured in Trypto -Soya broth (TSB, Nissui, for Streptococcus species) or in Brain Heart Infusion broth (BHIB, Difco, for other organism) for 18 hours at 37°C. Subcultures, which were incubated for 4 hours at 37°C after being suitably diluted with fresh TSB or BHIB, were suspended in the same amount of physiological saline (Streptococcus pneumoniae Type III) or 10% gastric mucin (Difco). A 0.5-ml volume of the bacterial suspension was injected intraperitoneally.
The challenge doses ranged from 2 to 10 times the minimal lethal doses. Under these conditions, all untreated mice died within 48 hours. The drugs were suspended in 0.3% carboxymethylcellulose and administered orally at 2 hours after infection, except E. coli GN2411-5 (1, 3 and 5 hours). The 50% effective dose (ED50) was calculated by the Litchfield-Wilcoxon method13) according to the numbers of survivors at 7 days after infection.
Respiratory Tract Infection: Acute bronchopneumonia in mice caused by K. pneumoniae F3740 was induced at described previously14). Male ICR mice weighing 18 to 20 g were placed in an exposure chamber (Okazaki Sangyo, Tokyo, Japan). A 10-ml of bacterial suspension ofK.pneumoniae F3740 (4, 1 x 109 cfu/ml), charged in a nebulizer (NE-llB, OMRON, Japan) was aerosolized with compressed air for 30 minutes. This resulted in a deposition of about 104cfu per lung, and no mice died within 3 days after infection. The antibiotics were administered orally to groups of five mice at 18, 21 and 24 hours after infection. At 20 hours after the last medication, lungs were removed aseptically, homogenized in 2ml of saline and viable bacterial cells were counted by conventional plating techniques.
Ascending Urinary Tract Infection: A modified method described by Oomori et al. 1 5) for experimental urinary tract infection in mice was used. Female 4-week-old mice weighing 18 to 20g were used. After restriction of water intake for 24 hours, mice were challenged by transurethral inoculation with 50/A of an E. coli GN2411-5 suspension (2.1 x 106 cfu/ml). Immediately afterwards, the external urethral meatus was clamped for 1 hour. Drug were administered orally to groups of five mice at 1, 3 and 5 hours after infection. At 24 hours after infection, kidney were removed aseptically and homogenized, and viable bacterial cells were counted by conventional plating techniques. In all of the untreated mice, the procedure gave rise to kidney infections with histopathological feature of pyelonephritis within 24 hours.
Results
Antibacterial Spectrum and Susceptibility of Clinical Isolates To assess the antibacterial spectrum of KT3777, its antibacterial activity against typical laboratory strains was compared with that of CCL, CEXand amoxicillin ( Table 1 ). The MICs of KT3777 ranged from 0.2 to 1. 56 //g/ml for Staphylococcus species, Streptococcus species, Micrococcus luteus, Bacillus subtilis, E. coli, K. pneumoniae, Proteus mirabilis and H. influenzae. KT3777 was inactive against methicillin-resistant S. aureus (MRSA),Proteus vulgaris, Morganella morganii, Enterobacter species, Serratia marcescens and Pseudomonas aeruginosa. The antibacterial spectrum and potency of KT3777against aerobes was considered to be similar to that of CCLbut slightly superior to that of CEX.KT3777inhibited some species of Gram-positive anaerobes, such as Peptostreptococcus, Propionibacterum and Eubacterium but showed no Agar dilution method, inoculum size 106 cfu/ml. a Agar dilution method; inoculum size 106 cfu/ml; 50 and 90%, MICof the antibiotic that inhibited 50 and 90%, respectively, of the isolates.
activity against Gram-negative anaerobes ( Table 2 ). The susceptibility of clinical isolates to KT3777 and the reference antibiotics is shown in Table 3 . The lowest concentration of KT3777 at which 50% of the clinical isolates were inhibited (MIC50) ranged from 0.2 to 3.13^g/ml for S. aureus, Streptococci, E. coli, K. pneumoniae, P. mirabilis, H. influenzae and N. gonorrhoeae (including penicillinase-producing strains). For Staphylococcus epidermidis, Proteus inconstans and Enterobacter cloacae, the MIC50of KT3777 ranged from 6.25 to 50/ig/ml. KT3777 showed little or no antibacterial activity against methicillin-resistant S.
aureus (MRSA), Enterococci, Citrobacter freundii, S. marcescens and Bacteroidesfragilis. The activity of KT3777was comparable to that of CCLagainst Staphylococci, Streptococci, H. influenzae and N.
gonorrhoeae. KT3777 showed slightly higher activity than CCL against several members of the Enterobacteriaceae, such as E. coli and K. pneumoniae. CEXwas 2 to 16 times inferior to KT3777 in activity against all Gram-positive and Gram-negative bacteria tested, in particular E. coli, K. pneumoniae, P. mirabilis and N. gonorrhoeae. The activity of amoxicillin against Streptococci, Enterococci and H. influenzae was much better than that of KT3777and the other antibiotics, whereas amoxicillin displayed weaker activity than KT3777against E. coli and K. pneumoniae.
Bactericidal
Activity Time-kill curves of KT3777 are shown in Fig. 2 . The bactericidal activity of KT3777 was compared with that of CCLand CEXagainst E. coli F3385 and K. pneumoniae F1928. Rapid reduction of cfu in E. coli F3385 was found with the addition of drugs at concentrations above the MIC(MICs: KT3777 and CCL, 1.56jug/ml; CEX, 12.5/xg/ml). Killing of more than 99% of the initial viable cells was achieved within 2 hours of incubation after exposure to these antibiotics at concentrations higher than the MIC. Moreover, no regrowth was observed during 24 hours of incubation at concentrations above the MIC. KT3777and the reference drugs exhibited bactericidal activity against K. pneumoniae at concentrations above the MIC (MICs: KT3777 and CCL, 3.13^g/ml; CEX, 12.5/ig/ml). Reductions in viability greater than 99% were seen with the addition of4-fold the MICof each drug within 4 to 6 hours. No regrowth occurred after exposure to 4-fold the MICof each drug up to 24 hours.
Binding Affinity for PBPs
The binding affinity of KT3777 for PBPs was compared with that of CCL. The results offluorography by competition of KT3777 with 14C-labeled benzylpenicillin for binding to PBPs of E. coli NIHJ JC-2 Mouse: ddY, $, 18-20g, n= l0. Challenge: ip. Therapy: po. ED50was determined by Litchfield-Wilcoxon method based on mice surviving 7 days after challenge.
are shown in Fig. 3 . KT3777 possessed moderate affinities for PBP1A (IC50, 2.7^^1), PBP3 (IC50, 3.6/xg/ml) and PBP4 (IC50, 2.6jug/ml), and relatively low affinity for PBP1B (IC50, 18.6/ig/ml). CCL also had moderate affinities for PBP1A (IC50, 5.9//g/ml), PBP1B (IC50, 9.8^g/ml), PBP3 (IC50, 2.5^g/ml) and PBP4 (IC50, l.liigjml).
KT3777 showed 2 to 3 times higher affinities for PBP1A and PBP4 than did CCL, whereas it had about 2 times lower affinity for PBP1B. Both KT3777 and CCL showed only poor affinities for PBP2, PBP5 and PBP6.
Therapeutic Effects In Vivo The protective effects of KT3777and the reference drugs against systemic infections in mice caused by a variety of pathogens are summarized in Table 4 . Against the mice infected with S. aureus Smith, S. pyogenes S 23, E. coli GN2411-5, E. coli F1095 and K. pneumoniae 8045, the protective effect of KT3777 The experiment was done as described in the text.
MIC Og/ml): KT3777 0.39, CCL 0.78.
was comparable to that ofCCL, and about 3 to 7 times greater than that of CEX. KT3777 was 3 to 5 times inferior to CCLagainst S. pneumoniae and P. mirahilis infections. Against S. pneumoniae infection, KT3777was slightly more active than CEX.The therapeutic efficacy of KT3777against acute pneumonia induced by K. pneumoniae F3740 in mice is shown in Fig. 4 . KT3777 was as effective as CCLand more effective than CEXin reducing the number of viable bacteria in the lungs. At a dose of 25mg/kg, the viable cell counts (log cfu/lung) were 2.40± 1.37 for KT3777, 2.67+0.57 for CCL, 4.33+0.62 for CEX, whereas they were 4.27+0.72 for the untreated control. The therapeutic effect of KT3777against an ascending urinary tract infection in mice caused by the transurethral inoculation of E. coli GN2411-5 was compared with that of CCL (Fig. 5) . Bacterial numbers increased to about 5.14cfu/kidney (log) in the untreated control. In contrast, treatment with oral doses of KT3777 led to a two log reduction in the numbers of viable cells. KT3777was comparable to CCLin reducing the numbers of viable bacteria in the kidney. Discussion
In this report, the in vitro and in vivo antibacterial activities of KT3777were compared with CCL16'17), CEXand amoxicillin, which were commercially available oral /Mactam antibiotics. KT3777 exhibited good antibacterial activity against S. aureus, Streptococci, E. coli, K. pneumoniae, P. mirabilis, H. influenzae and N. gonorrhoeae. Its activity was comparable to that of CCLand higher than that of CEX. However, KT3777 showed higher activity than CCLagainst several members of the Enterobacteriaceae, such as E. coli and K. pneumoniae, suggesting an advantage for these species. KT3777 also inhibited Gram-positive anaerobes, such as Peptostreptococcus, Propionibacterium and Eubacterium.
Like first generation cephalosporins, KT3777 showed poor or no antibacterial activity against methicillin-resistant S. aureus, Enterococci, C.freundii, S. marcescens, P. aeruginosa and B.fragilis. KT3777 showed bactericidal activity at MICconcentrations or greater against E. coli and K. pneumoniae. This activity was similar to that of CCLand slightly superior to that of CEX. KT3777is more stable to plasmid-mediated /Mactamases than CCL7~9). In our studies, KT3777 had a /Mactamase stability slightly superior to or similar to that of CCLagainst various./Mactamase producing clinical isolates (data not shown). KT3777 possessed high affinities for PBP1A, PBP3 and PBP4 ofE. coli NIHJ JC-2, and moderate affinity for PBP1B. KT3777 also showed less affinities for PBP2, PBP5 and PBP6. KT3777 showed 2 to 3 times higher affinities for PBP1Aand PBP4 than CCL, whereas it was about 2 times lower affinity for PBP1B than CCL. Against systemic infections, the protective effect of KT3777after oral dosing was almost comparable to that of CCL, with the exception of S. pneumoniae and P. mirabilis infections. KT3777was uniformly more effective than CEXagainst bacterial systemic infections tested. Furthermore against localized infections such as acute pneumonia and ascending pyelonephritis in mice, KT3777was as effective as CCLin reducing the numbers of viable bacteria in the target organ (lung or kidney).
We have confirmed two advantages in our previous experiments. That is, KT3777 has greater bioavailability and greater chemical stability than CCL(under preparation).
In conclusion, KT3777 is the first carbacephem antibiotic for oral use. These results of laboratory studies suggest that this compound would be useful in the clinical treatment of bacterial infections. Recently, clinical efficacy studies of KT3777 have been started.
